Corneal inflammatory cell infiltration predicts disease activity in chronic inflammatory demyelinating polyneuropathy

Jeremias Motte1,2,6, Thomas Grüter1,2,6, Anna Lena Fisse1,2, Yesim Bulut1,2, Zornitsa Stykova1,2, Tineke Greiner3, Elena Enax-Krumova2,3, Min-Suk Yoon2,4, Ralf Gold1,2, Martin Tegenthoff2,3, Dietrich Sturm2,3,5,6 & Kalliopi Pitarokoili1,2,6

The assessment of disease activity is fundamental in the management of chronic inflammatory demyelinating polyneuropathy (CIDP). Previous studies with small patient numbers found an increase of corneal immune cell infiltrates as a potential marker of inflammation in patients with CIDP. However, its clinical relevance remained unclear. The present study aimed to determine whether the amount of corneal inflammatory cells (CIC) measured by corneal confocal microscopy (CCM) detects disease activity in CIDP. CIC were measured in 142 CCM-investigations of 97 CIDP-patients. Data on clinical disease activity, disability (INCAT-ODSS) and need for therapy escalation at the timepoint of CCM, 3 and 6 months later were analyzed depending CIC-count. Pathological spontaneous activity during electromyography was examined as another possible biomarker for disease activity in comparison to CIC-count. An increased CIC-count at baseline was found in patients with clinical disease activity and disability progression in the following 3–6 months. An increase to more than 25 CIC/mm² had a sensitivity of 0.73 and a specificity of 0.71 to detect clinical disease activity and a sensitivity of 0.77 and a specificity of 0.64 to detect disability progression (increasing INCAT-ODSS) in the following 6 months. An increase to more than 50 CIC/mm² had a sensitivity of about 0.51 and a specificity of 0.91 to detect clinical disease activity and a sensitivity of 0.53 and a specificity of 0.80 to detect disability progression. CIC count is a non-invasive biomarker for the detection of disease activity in the following 6 months in CIDP.

Markers of disease activity are essential for adequate clinical management and therapy monitoring in chronic inflammatory demyelinating polyneuropathy (CIDP). Up to 30% of all CIDP patients require a therapy escalation due to an aggressive disease course. In such patients, early therapy adjustment appears to prevent clinical disability. Therefore, early and reliable biomarkers are essential to detect patients at risk with active disease course. However, disease activity in CIDP is difficult to determine. The CIDP disease activity status (CDAS) is a simple score for clinical disease activity, however this score was validated to classify the long-term outcome and response to treatment in CIDP. Established methods such as nerve conduction studies (NCS) can indicate disease progression but are often delayed. In the chronic progressive disease phase, identification of an ongoing progression in NCS can be challenging due to a high degree of axonal damage. Electromyography (EMG) can detect pathological spontaneous activity (PSA), demonstrating denervation and axonal damage. Nevertheless, PSA might persist several months to years after axonal damage making it also not suitable as a dynamic biomarker. Thus, PSA can serve rather as a marker for disease progression in a long-term setting, as recently shown by our group.

Corneal confocal microscopy (CCM) is a non-invasive method to image the corneal subbasal nerve plexus as well as cellular corneal elements like corneal inflammatory cells (CIC). It is assumed that the majority of CIC are located in the subbasal nerve plexus. Previous studies have shown that CIC are increased in patients with active disease, however the clinical relevance of this finding remained unclear. The present study aimed to determine whether the amount of corneal inflammatory cells (CIC) measured by corneal confocal microscopy (CCM) detects disease activity in CIDP. CIC were measured in 142 CCM-investigations of 97 CIDP-patients. Data on clinical disease activity, disability (INCAT-ODSS) and need for therapy escalation at the timepoint of CCM, 3 and 6 months later were analyzed depending CIC-count. Pathological spontaneous activity during electromyography was examined as another possible biomarker for disease activity in comparison to CIC-count. An increased CIC-count at baseline was found in patients with clinical disease activity and disability progression in the following 3–6 months. An increase to more than 25 CIC/mm² had a sensitivity of 0.73 and a specificity of 0.71 to detect clinical disease activity and a sensitivity of 0.77 and a specificity of 0.64 to detect disability progression (increasing INCAT-ODSS) in the following 6 months. An increase to more than 50 CIC/mm² had a sensitivity of about 0.51 and a specificity of 0.91 to detect clinical disease activity and a sensitivity of 0.53 and a specificity of 0.80 to detect disability progression. CIC count is a non-invasive biomarker for the detection of disease activity in the following 6 months in CIDP.

1Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Gudrunstrasse 56, 44791 Bochum, Germany. 2Immunmediated Neuropathies Biobank (INHIBIT), Ruhr-University Bochum, Bochum, Germany. 3Department of Neurology, Bergmannsheil University Hospital, Ruhr University, Bochum, Germany. 4Department of Neurology, Evangelisches Krankenhaus Hattingen, Hattingen, Germany. 5Department of Neurology, Agaplesion Bethesda Krankenhaus, Wuppertal, Germany. 6These authors contributed equally: Jeremias Motte, Thomas Grüter, Dietrich Sturm and Kalliopi Pitarokoili. *email: Jeremias.Motte@rub.de
these immunological cells are antigen presenting cells like Langerhans cells\textsuperscript{14}. However, also other types of cell populations can be identified by morphological and biochemical features\textsuperscript{14–17}. The number of CIC can be elevated in systemic inflammatory diseases like rheumatoid arthritis\textsuperscript{18}. We previously reported that CIC count could be a prognostic marker for disease activity in a small cohort of 17 CIDP patients\textsuperscript{19}. However, their clinical relevance is yet to be confirmed due to a lack of a prospective clinical follow-up assessment so far.

Aim of the present longitudinal study was to validate the CIC count in CCM as a reliable biomarker for the detection of disease activity in CIDP.

Methods

Patients. In total, 97 CIDP patients were recruited and prospectively analyzed regarding demographic, clinical, and treatment data during November 2015 and December 2019. All patients gave their informed consent prior to their inclusion in the study. Ethics committee of the Ruhr-University Bochum approved the study (Bio-Nerve; vote-no. 4905-14, as well as Immunmediated Neuropathies Biobank INHIBIT; vote-no. 18-6534-BR). Patients were diagnosed in accordance with the diagnostic and electrophysiological criteria of European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS)\textsuperscript{20}. CIDP was further differentiated in typical and atypical CIDP in accordance to Doneddu et al.\textsuperscript{21}.

Study design. The study was performed as a two-center prospective observational study in the Department of Neurology, University Hospital—St. Josef-Hospital, Ruhr-University Bochum, and the Department of Neurology, BG University Hospital Bergmannsheil gGmbH, Ruhr-University Bochum, Germany.

After power analysis using G\textsuperscript{Power} (version 3.1.9.6, Heinrich-Heine-Universität Düsseldorf, Germany) resulting in 136 needed patients to depict an effect size of 0.64 with a p ≤ 0.05 we analyzed data of 142 data sets. Ninety-seven consecutive CIDP patients were prospectively included, 28 of them underwent more than one CCM examination (two examinations n = 28, three examinations n = 13, four examinations n = 4), resulting in additional 45 CCM sets. They were analyzed as separate data sets as they were more than 6 months apart from the baseline CCM. Every CCM examination was defined as at time-point zero (TP.0). Patients underwent clinical examination at TP0 as well as three (TP.3) and six (TP.6) months after CCM. Different, blinded investigators performed CCM and clinical examination. An overview of the study design is shown in Fig. 1.

Conical confocal microscopy. All CCM were executed by TGre and DS using a Heidelberg Retinal Tomograph III with a Rostock Cornea Module (Heidelberg Engineering GmbH, Heidelberg, Germany) as previously described\textsuperscript{22}. Five high-quality images of one eye were analyzed with ACC-Metrics software, version 2.0 (Manchester, United Kingdom)\textsuperscript{23}. CIC were counted manually by DS and reported as total cell count per mm\textsuperscript{2}. We summarized all immunological cells in this analysis as CIC. The CCM examiners were blinded for the clini-
Electromyography. Electromyographic examination as an invasive method was not performed as part of this study, but if EMG evaluation was carried out in clinical routine independently from the study on indication of the treating physician at TP0, results were collected and were included in the analysis. Needle EMG was performed with a Dantec™ Keypoint™ G4 four channel electromyography device (Natus Europe GmbH, Planegg, Germany) and corresponding disposable concentric monopolar needle electrode 50 × 0.46 mm with 0.07 mm² recording area (Value Line DCN, Natus, Ireland) as described in Stöhr et al.24. PSA was sampled in the tibial anterior muscle in ten different needle locations each observed for 10 s. PSA was considered if fibrillations and positive sharp waves occurred in more than 10% of the analyzed needle positions24. Pathological spontaneous activity in EMG was considered as other possible biomarker for disease activity for comparison to CIC count. EMG was available in 55 cases. The presence of PSA at TP0 was compared to disease activity at TP0, TP3 and TP6 measured by the outcome parameters described below. Moreover, PSA at TP0 was directly compared to CIC count at TP0.

Definition of outcome parameters. To assess the disease activity, three outcome parameters were obtained (definition of see section below):

1. clinical disease activity
2. worsening or stability of Inflammatory Neuropathy Cause and Treatment overall disability score (INCAT-ODSS)
3. need for therapy escalation.

Clinical disease activity. Expert neurologists (JM, ALF, TGrü) were blinded to CIC count and EMG and assessed the patients for disease activity based on their medical history, the clinical course and in consultation with the independent treating physicians. The disease was categorized in 'active' or 'stable'.

INCAT-ODSS. Disability was quantified by two examiners (JM and ALF) using INCAT-ODSS as current gold standard for clinical disability of CIDP patients25, 3 months before TP0, at TP0, TP3 and TP6. Stability was defined as no change of INCAT-ODSS for 3 months before each timepoint. Instability was defined as an increase of at least one INCAT-ODSS point 3 months before each timepoint.

Need for therapy escalation. Therapy escalation was defined as:

a) New application or dosage increase of a first-line treatment with intravenous immunoglobulins, corticosteroids or plasma exchange.

b) New application of an immunotherapy other than first-line treatment (i.e. azathioprine, mycophenolate, cyclosporine, or rituximab).

Statistics. Statistical analysis was performed using IBM® SPSS Statistics (version 26.0.0.0). Clinical outcome parameter and CIC count were compared using Mann–Whitney test (Shapiro–Wilk test of normality was significant) and Chi-squared ($\chi^2$-test) for nominal variables. To measure the association of two binary variables phi coefficient ($\phi$) was used. To determine the optimal threshold value of CIC count as disease activity marker for the following 6 months and its specificity and sensitivity, a receiver-operator-characteristic (ROC) curve was created. The area under the curve (AUC) and potential cut-off points of the CIC count were calculated. A single cut-off value was limited either to specificity or to sensitivity. To get a balanced compromise of sensitivity and specificity, two cut-off values were validated.

In case of multiple testing the Holm–Bonferroni method was used as correction. For all analyses, the statistically significant threshold was set at a p-value of < 0.05. We calculated needed effect size per sample size calculations provided by G*Power (http://www.gpower.hhu.de).

Ethical approval. All procedures performed in studies involving human participants were in accordance with the ethical standard of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendment or comparable ethical standards. The study was approved by the local ethics committee.

Patient and public involvement. The patients gave spoken and written consent for publication and participation to the study.

Results

Clinical data. The study cohort included 97 patients, 71 male (73%) and 26 female (27%). Mean age was 56.9 years (± 13.1) and mean disease duration 4.9 years (± 4.5). The mean INCAT-ODSS at TP0 was 3.1 (± 1.9). All 97 patients had a CIDP, 49 of them had typical CIDP (50.5%) and 48 had atypical CIDP (49.5%).
CIC count as biomarker of disease activity. Patients who were categorized as clinically active at TP0 and TP3 had a significantly higher CIC count than patients who were clinically stable. At TP6 patients with clinical activity did not have a higher CIC count than patients with stable clinical course.

Similarly, patients with worsening of INCAT-ODSS at TP0 and TP3 showed a significant higher CIC count than patients with stable INCAT-ODSS. Representative CCM images are shown in Fig. 2. For INCAT-ODSS worsening at TP6 this association was not found.

Patients with indication for treatment escalation did not show a higher CIC count than patients without need for therapy escalation at any timepoint (Table 1).

Cut-off value, specificity and sensitivity of CIC count to detect active disease. We conducted a ROC-analysis to calculate the clinically relevant cut-off value of CIC count for detection of disease activity.

The AUC_ROC to detect clinical activity at TP0 was 0.78 (p = 0.0001, 95% CI 0.70–0.86), the AUC_ROC to detect INCAT-ODSS worsening in the following 6 months 0.73 (p = 0.0001, 95% CI 0.63–0.83) indicating CIC count as a fair method to detect current and early disease activity (Fig. 3A,B).

CIC count to detect current disease activity. A CIC count of more than 25 cells/mm² detects a current disease activity with a sensitivity of 0.73 and a specificity of 0.71. Patients with a CIC count > 25 cells/mm² had higher current disease activity than patients with a CIC count ≤ 25 cells/mm² ($\chi^2 = 35.40$, p = 0.0001). Phi coefficient for the association of CIC count > 25 cells/mm² and disease activity at TP0 was $\phi = 0.431$.

A CIC count of more than 50 cells/mm² detects a current disease activity with a sensitivity of 0.51 and a specificity of 0.91. Patients with a CIC count > 50 cells/mm² had higher current disease activity than patients with

| Cell count at TP0 median (range) | Cell count at TP0 median (range) | Cell count at TP0 median (range) |
|---------------------------------|---------------------------------|---------------------------------|
| Clinical stable at TP0 (n = 74) | 14 (0–349)                      | INCAT-ODSS stable at TP0 (n = 119) | 18 (0–365) | No therapy escalation at TP0 (n = 97) | 20 (1–365) |
| Clinical active at TP0 (n = 61) | 54 (0–365)                      | INCAT-ODSS instable at TP0 (n = 22) | 54 (1–135) | Therapy escalation at TP0 (n = 40) | 28 (0–194) |
| p-value                         | 0.0009                          | p-value                         | 0.018      | p-value                         | n.s.      |
| Clinical stable at TP3 (n = 80) | 16 (1–365)                      | INCAT-ODSS stable at TP3 (n = 93) | 19 (0–365) | No therapy escalation at TP3 (n = 78) | 16 (0–365) |
| Clinical active at TP3 (n = 20) | 54 (0–181)                      | INCAT-ODSS instable at TP3 (n = 9) | 64 (16–158) | Therapy escalation at TP3 (n = 22) | 31 (3–181) |
| p-value                         | 0.016                           | p-value                         | 0.016      | p-value                         | n.s.      |
| Clinical stable at TP6 (n = 79) | 19 (3–349)                      | INCAT-ODSS stable at TP6 (n = 79) | 20 (3–349) | No therapy escalation at TP6 (n = 80) | 23 (3–349) |
| Clinical active at TP6 (n = 14) | 32 (0–163)                      | INCAT-ODSS instable at TP6 (n = 14) | 32 (0–194) | Therapy escalation at TP6 (n = 12) | 32 (3–158) |
| p-value                         | n.s.                            | p-value                         | n.s.      | p-value                         | n.s.      |

Table 1. Corneal inflammatory cell count at TP0 and on outcome in the following 6 months. p-values were corrected by the Holm–Bonferroni method, groups were formed according to the outcome parameter. The different n-values at TP0, TP3 and TP6 are a result of “loss to follow-up”.

Figure 2. Representative CCM image of a stable patient (A) and an active patient (B). The arrows point to axons of the corneal nerves in (A) and to corneal inflammatory cells in (B). CCM confocal corneal microscopy.
a CIC count ≤ 50 cells/mm² ($\chi^2 = 28.28$, $p = 0.0001$). Phi coefficient for the association of CIC count > 50 cells/mm² and disease activity at TP.0 was $\phi = 0.458$.

CIC count to detect INCAT-ODSS worsening in the next 6 months. A CIC count of more than 25 cells/mm² detects an INCAT-ODSS worsening in the next 6 months with a sensitivity of 0.77 and a specificity of 0.64. Patients with a CIC count of > 25 cells/mm² more often had a worsening of INCAT-ODSS than patients with a CIC count ≤ 25 cells/mm² ($\chi^2 = 16.43$, $p = 0.0001$). Phi coefficient for the association of CIC count > 25 cells/mm² and disease activity at TP.0 was $\phi = 0.345$.

A CIC count of more than 50 cells/mm² detects an INCAT-ODSS worsening in the next 6 months with a sensitivity of 0.53 and a specificity of 0.80. The patients with a CIC count > 50 cells/mm² more often had a worsening of INCAT-ODSS than patients with a CIC count ≤ 50 cells/mm² ($\chi^2 = 14.07$, $p = 0.0001$). Phi coefficient for the association of CIC count > 50 cells/mm² and disease activity at TP.0 was $\phi = 0.322$.

CIC count to detect need for therapy escalation. A number of 55 EMG were available at TP.0. PSA correlated with none of the outcome parameters, i.e. neither with the clinical disease activity, nor with the INCAT-ODSS worsening or the need for therapy escalation at time point of CCM (TP.0), three (TP.3) and six (TP.6) months after CCM.

Patients with PSA did not show a higher CIC count than patients without PSA (median cell count in patients with PSA 21.3/mm², median cell count in patients without PSA 21.9/mm², $p = 0.636$).

Discussion

The main result of our study is that the amount of CIC is a noninvasive biomarker for current and short-term disease activity in CIDP, measured by clinical assessment and INCAT-ODSS. CIC count as a diagnostic test for current disease activity has a fair test quality. A CIC count of more than 25 cells/mm² has a good sensitivity (77%) and a value of more than 50 cells/mm² has a good specificity (80%) to detect INCAT-ODSS progression in the following 6 months.

Similar, a CIC count of more than 25 cells/mm² has a good sensitivity (73%) and a value of more than 50 cells/mm² has a good specificity (91%) to detect current disease activity.

We therefore suggest that patients with more than 25 cells/mm² should be monitored closely clinically and a CIC count of more than 50 cells/mm² should result in an expectation of a disease deterioration. When assessing disease activity with CIC a good sensitivity and specificity are important as these values means good positive and negative predictive values. This should not be misunderstood as sensitivity and specificity to diagnose a certain inflammatory neuropathy but only to detect disease activity within the group of CIDP. CIC can be compared to leukocytes, which are not specific for infectious diseases but could still be used as an activity marker in systemic infections. Whether CIC is increased only on inflammatory neuropathies or in polyneuropathies with inflammatory activity remains to be evaluated in studies with multiple groups of patients with different polyneuropathies and controls. Our data implicate that patients with risk of clinical deterioration can be identified early by measuring CIC count. That is important because early therapy escalation in inflammatory neuropathies has been described as beneficial. However, CCM does not allow therapeutic decisions based solely on the CIC count. Only a bundle of different diagnostic methods describes the individual risk of disease activity in CIDP.
In contrast to CIC infiltration, PSA in EMG represents axonal damage. We have recently reported about PSA as a prognostic marker for CIDP patients in a long-term cohort study\(^{10}\). PSA is suitable to predict long-term clinical progression beyond 7 months\(^{11}\). We suppose that CIC infiltration represents an “active state” of inflammation, as it correlates to current disease activity, whereas over time, the correlation of CIC count and disease activity decreases. Therefore, CIC count is a marker for acute disease activity, while PSA as a sign of axonal damage has a long-term prognostic relevance. The corneal nerve fiber parameters might be a marker of axonal damage as well, but were not analyzed in this study since the longitudinal period of evaluation was very short and this parameter did not change (data not shown). Corneal nerve fiber reduction was shown in several types of neuropathy including immune-mediated neuropathies\(^{26–28}\), however acute upcoming disease activity was not analyzed in these studies. Taken together, both information, acute cell infiltration and axonal damage, are important but different aspects of the disease\(^4\).

Previous studies documented an increase of CIC count in CIDP compared to healthy controls\(^{26,27}\). One of these studies showed a relation between the clinical phenotype of CIDP and the number of CIC: patients with predominant motoric symptoms had the highest numbers of CIC. Besides, a direct contact of the CIC to corneal axons were described in inflammatory neuropathies\(^{22}\). We did not analyze these clinical and morphological features, which is a limitation of this study. Further histological in vivo assessment of the corneal subbasal plexus and different cell populations in animal models of autoimmune neuropathies might help to clarify the pathophysiological role of CIC.

We did not find an association between CIC count and therapy escalation. The main reason for that probably is, that escalation of therapy occurs delayed and therefore was not recorded in the 6 months follow-up period. Escalation therapy for example with cyclophosphamide or rituximab are off-label and are used cautiously which could lead to a delayed decision. A therapy escalation in CIDP has not yet been investigated in controlled studies, but only in retrospective or uncontrolled trails.

The CDAS-score\(^7\) is an assessment tool for clinical disease activity and was validated for the long-term outcome and response to treatment in CIDP. In this study we did not use this score as outcome parameter as we want examine a short-term outcome parameter. However, an evaluation of the CIC as inflammatory marker and PSA as axonal marker in relation to the CDAS is a useful approach for register studies that examine long-term outcome of CIDP.

This study has three important limitations. First, it was carried out at only two tertiary centers potentially including patients with complex medical history. However, the CCM examination was carried out and analyzed blinded and independent from decisions regarding patients’ treatment. Second, there is no control group with healthy volunteers in the study protocol. However, in this pilot study we focused on short-term follow up analysis of intraindividual changes. This study did not show that the CIC is different between active CIDP and healthy controls, but between active and stable CIDP patients. Previous studies show that CIC is lower in healthy controls\(^{26,29–31}\). Last, several ophthalmologic and metabolic diseases may also influence the amount of CIC or the subbasal plexus\(^{17,32–34}\). Nevertheless, serious ophthalmic diseases were always enquired before CCM examination.

In conclusion, measurement of the CIC count is a non-invasive biomarker for assessing the disease activity in CIDP patients. CIC count detects current and future disease activity in a period up to 6 months. Therefore, CCM should be used more frequently for monitoring CIDP patients. Further studies are necessary to understand the pathophysiology behind CIC infiltration in inflammatory neuropathies.

Data availability
Data collected from this study are available by emailing jeremias.motte@rub.de.

Received: 29 October 2020; Accepted: 7 July 2021
Published online: 26 July 2021

References
1. Yoon, M.-S., Chan, A. & Gold, R. Standard and escalating treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Ther. Adv. Neurol. Disord. 4, 193–200 (2011).
2. Dalakas, M. C. Advances in the diagnosis, pathogenesis and treatment of CIDP. Nat. Rev. Neurol. 7, 507–517 (2011).
3. Ellrichmann, G., Gold, R., Ayzenberg, I., Yoon, M.-S. & Schneider-Gold, C. Two years’ long-term follow up in chronic inflammatory demyelinating polyradiculoneuropathy: Efficacy of intravenous immunoglobulin treatment. Ther. Adv. Neurol. Disord. 10, 91–101 (2017).
4. Motte, J. et al. Treatment response to cyclophosphamide, rituximab, and bortezomib in chronic immune-mediated sensorimotor neuropathies: A retrospective cohort study. Ther. Adv. Neurol. Disord. 14, 175628642199963 (2021).
5. Fisse, A. L. et al. Comprehensive approaches for diagnosis, monitoring and treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Neurol. Res. Pract. 2, 42 (2020).
6. Lehmann, H. C., Burke, D. & Kuwabara, S. Chronic inflammatory demyelinating polyneuropathy: Update on diagnosis, immunopathogenesis and treatment. J. Neurol. Neurosurg. Psychiatry 90, 981–987 (2019).
7. Albulaïhe, H. et al. Disease activity in chronic inflammatory demyelinating polyneuropathy. J. Neurol. Sci. 369, 204–209 (2016).
8. Décard, B. F., Pham, M. & Grimm, A. Ultrasound and MRI of nerves for monitoring disease activity and treatment effects in chronic dysimmune neuropathies—Current concepts and future directions. Clin. Neuropathol. 129, 155–167 (2018).
9. Allen, J. A. & Lewis, R. A. CIDP diagnostic pitfalls and perception of treatment benefit. Neurology 85, 498–504 (2015).
10. Grüter, T. et al. Pathological spontaneous activity as a prognostic marker in chronic inflammatory demyelinating polyneuropathy. Eur. J. Neurol. 27, 2595–2603 (2020).
11. Wang, E. F., Misra, S. L. & Patel, D. V. In vivo confocal microscopy of the human cornea in the assessment of peripheral neuropathy and systemic diseases. Biomed. Res. Int. 2015, 951081 (2015).
12. Zhovtiv, A., Stave, I., Vollmar, B. & Guthoff, R. In vivo confocal microscopic evaluation of Langerhans cell density and distribution in the corneal epithelium of healthy volunteers and contact lens wearers. Cornea 26, 47–54 (2007).
13. Choi, E. Y. et al. Langerhans cells prevent subbasal nerve damage and upregulate neurotrophic factors in dry eye disease. PLoS One 12, e0176153 (2017).
14. Albulaihe, H.
15. Décard, B. F., Pham, M. & Grimm, A. Ultrasound and MRI of nerves for monitoring disease activity and treatment effects in chronic inflammatory demyelinating polyneuropathy. Clin. Neurophysiol. 129, 155–167 (2018).
16. Wang, E. F., Misra, S. L. & Patel, D. V. In vivo confocal microscopy of the human cornea in the assessment of peripheral neuropathy and systemic diseases. Biomed. Res. Int. 2015, 951081 (2015).
17. Zhovtiv, A., Stave, I., Vollmar, B. & Guthoff, R. In vivo confocal microscopic evaluation of Langerhans cell density and distribution in the corneal epithelium of healthy volunteers and contact lens wearers. Cornea 26, 47–54 (2007).
18. Choi, E. Y. et al. Langerhans cells prevent subbasal nerve damage and upregulate neurotrophic factors in dry eye disease. PLoS One 12, e0176153 (2017).
19. Albulaïhe, H. et al. Disease activity in chronic inflammatory demyelinating polyneuropathy. J. Neurol. Sci. 369, 204–209 (2016).
20. Décard, B. F., Pham, M. & Grimm, A. Ultrasound and MRI of nerves for monitoring disease activity and treatment effects in chronic dysimmune neuropathies—Current concepts and future directions. Clin. Neuropathol. 129, 155–167 (2018).
21. Allen, J. A. & Lewis, R. A. CIDP diagnostic pitfalls and perception of treatment benefit. Neurology 85, 498–504 (2015).
22. Grüter, T. et al. Pathological spontaneous activity as a prognostic marker in chronic inflammatory demyelinating polyneuropathy. Eur. J. Neurol. 27, 2595–2603 (2020).
23. Wang, E. F., Misra, S. L. & Patel, D. V. In vivo confocal microscopy of the human cornea in the assessment of peripheral neuropathy and systemic diseases. Biomed. Res. Int. 2015, 951081 (2015).
24. Zhovtiv, A., Stave, I., Vollmar, B. & Guthoff, R. In vivo confocal microscopic evaluation of Langerhans cell density and distribution in the corneal epithelium of healthy volunteers and contact lens wearers. Cornea 26, 47–54 (2007).
25. Choi, E. Y. et al. Langerhans cells prevent subbasal nerve damage and upregulate neurotrophic factors in dry eye disease. PLoS One 12, e0176153 (2017).
edge support by the Open Access Publication Funds of the Ruhr-Universität Bochum.

This research from any funding agency in the public, commercial or not-for-profit sectors. The authors acknowledge Open Access funding enabled and organized by Projekt DEAL. The authors have not declared a specific grant for this research, nor are they employed by, nor hold stock or significant ownership in a company that may as a conflict of interest, with respect to the materials discussed in this manuscript.

The authors declare no competing interests.

Correspondence

Additional information

The authors declare no competing interests.

Author contributions

J.M.: Basic idea, data collection, statistical analysis, drafting and revising the manuscript. T.G.: Data collection and revising the manuscript. A.L.F.: Data collection and revising the manuscript. Y.B.: Data collection. Z.S.: Data collection. T.G.: Data collection. E.K.E.-K.: Data collection and revising the manuscript. M.-S.Y.: Critical comments during data collection, drafting and manuscript revision. R.G.: Critical comments during data collection, drafting and manuscript revision. M.T.: Critical comments during data collection, drafting and manuscript revision. D.S.: Basic idea, data collection, analysis of corneal cells, drafting and revising the manuscript. K.P.: Basic idea, critical comments during data collection, drafting and manuscript revision.

Funding

Open Access funding enabled and organized by Projekt DEAL. The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors. The authors acknowledge support by the Open Access Publication Funds of the Ruhr-Universität Bochum.

Competing interests

The authors declare no competing interests.

Additional information

Correspondence and requests for materials should be addressed to J.M.

Reprints and permissions information

is available at www.nature.com/reprints.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
